US Pharma MarketingCeQur nabs $100M series E to fuel insulin patch commercialization
Swiss medtech CeQur has raised $100 million in a new series E funding round for what it called its “most ambitious phase of commercial growth.” Swiss medtech CeQur has raised $100 million in a series E funding round for what it called its “most ambitious phase of commercial growth.” Biotech Cell & Gene Therapy Clinical Data Venture Capital Deals Research Medtech Devices Diagnostics AI and Machine Learning CRO Special Reports Trending Biologics Clinical Development Ophthalmology Cell & Gene Therapy Drug Development Small Molecule Research & Development Fierce 50 Special Report Awards Gala Awards Outsourcing Awards Innovation Awards Resources Fierce…
Swiss medtech CeQur has raised $100 million in a series E funding round for what it called its “most ambitious phase of commercial growth.”
Source: FierceBiotech